Cargando…

M62. PERIPHERAL INFLAMMATION MARKERS IDENTIFY SUBSET OF PATIENTS WITH SCHIZOPHRENIA AND RELATED PSYCHOSES WHO HAVE INTELLECTUAL DECLINE FROM PREMORBID LEVELS

BACKGROUND: Higher inflammation has been identified in a substantial subset of both high-risk and chronically ill patients with schizophrenia and related psychoses and this may account for some of the heterogeneity of the schizophrenia. There is also much heterogeneity in cognitive deficits related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weickert, Thomas, Ramanathan, Seetha, Lenroot, Rhoshel, Liu, Dennis, Balzan, Ryan, Galletly, Cherrie, Shannon Weickert, Cynthia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session II
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233845/ http://dx.doi.org/10.1093/schbul/sbaa030.374

Ejemplares similares

C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls
por: Jacomb, Isabella, et al.
Publicado: (2018)

M99. INVESTIGATING THE BEST PREDICTIVE CLINICAL FEATURES OF ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS IN THE 2010 AUSTRALIAN NATIONAL SURVEY OF HIGH IMPACT PSYCHOSIS (SHIP) COHORT
por: Rossell, Susan, et al.
Publicado: (2020)

The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes
por: Wells, Ruth, et al.
Publicado: (2015)

Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia
por: Kindler, Jochen, et al.
Publicado: (2019)

M174. REDUCED CHEMOKINE SIGNALLING CAPACITY IS ASSOCIATED WITH INHIBITORY INTERNEURON DYSFUNCTION IN SUBCORTICAL BRAIN REGIONS IN SCHIZOPHRENIA AND BIPOLAR DISORDER
por: Weissleder, Christin, et al.
Publicado: (2020)

Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder
por: Boerrigter, Danny, et al.
Publicado: (2017)

O1.5. ICAM-1 IS INCREASED IN BRAIN AND PERIPHERAL LEVELS OF SOLUBLE ICAM-1 IS RELATED TO COGNITIVE DEFICITS IN SCHIZOPHRENIA
por: Weickert, Thomas, et al.
Publicado: (2018)

M151. DIFFERENCES IN PATTERN OF OBESITY BETWEEN PEOPLE WITH SCHIZOPHRENIA LIVING IN CHINA AND IN AUSTRALIA
por: Galletly, Cherrie, et al.
Publicado: (2020)

Testosterone Is Inversely Related to Brain Activity during Emotional Inhibition in Schizophrenia
por: Vercammen, Ans, et al.
Publicado: (2013)

Selective Estrogen Receptor Modulation Increases Hippocampal Activity during Probabilistic Association Learning in Schizophrenia
por: Kindler, Jochen, et al.
Publicado: (2015)

M131. RETURN TO LABOUR MARKET IN SCHIZOPHRENIA AND OTHER PSYCHOSES – THE NORTHERN FINLAND BIRTH COHORT 1966
por: Majuri, Tuomas, et al.
Publicado: (2020)

Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation
por: Cai, Helen Q., et al.
Publicado: (2018)

Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases
por: Murphy, Caitlin E., et al.
Publicado: (2022)

Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia
por: Weickert, T W, et al.
Publicado: (2015)

A Brief Assessment of Intelligence Decline in Schizophrenia As Represented by the Difference between Current and Premorbid Intellectual Quotient
por: Ohi, Kazutaka, et al.
Publicado: (2017)

Brain antibodies in the cortex and blood of people with schizophrenia and controls
por: Glass, L J, et al.
Publicado: (2017)

Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia
por: Skilleter, A. J., et al.
Publicado: (2015)

Raloxifene Improves Cognition in Schizophrenia: Spurious Result or Valid Effect?
por: Weickert, Thomas W., et al.
Publicado: (2017)

15. ON THE ROAD TO CURING SCHIZOPHRENIA
por: Weickert, Cynthia Shannon
Publicado: (2018)

Genetic variation in glutamatergic genes moderates the effects of childhood adversity on brain volume and IQ in treatment-resistant schizophrenia
por: Mohamed Saini, Suriati, et al.
Publicado: (2023)

O11.2. ELEVATION OF MACROPHAGE-RELATED TRANSCRIPTS IN THE MIDBRAIN IN SCHIZOPHRENIA
por: Purves-Tyson, Tertia, et al.
Publicado: (2020)

Metacognitive therapy (MCT+) in patients with psychosis not receiving antipsychotic medication: A case study
por: Balzan, Ryan P., et al.
Publicado: (2015)

Common polymorphisms in dopamine-related genes combine to produce a ‘schizophrenia-like' prefrontal hypoactivity
por: Vercammen, A, et al.
Publicado: (2014)

S165. GLUTAMATERGIC ABNORMALITIES IN EARLY SCHIZOPHRENIA AND BIPOLAR DISORDER MEASURED USING WHOLE-BRAIN SPECTROSCOPY
por: Lenroot, Rhoshel, et al.
Publicado: (2020)

Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder
por: Fillman, S G, et al.
Publicado: (2014)

T236. TECHNOLOGY LITERACY AND ENGAGEMENT IN PEOPLE WITH SCHIZOPHRENIA
por: Wong, Kwok Tung Gordon, et al.
Publicado: (2018)

Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume
por: Fillman, S G, et al.
Publicado: (2016)

T232. PREMORBID SOCIAL FUNTIONING AND AFFECTIVE SYMTPOMS ARE RELATED TO SUBJECTIVE OUTCOME AMONG OUTPATIENTS WITH SCHIZOPHRENIA
por: Hörtnagl, Christine, et al.
Publicado: (2020)

Smartphone and Internet Access and Utilization by People With Schizophrenia in South Australia: Quantitative Survey Study
por: Wong, Kwok Tung Gordon, et al.
Publicado: (2020)

S80. CHILDHOOD TRAUMA AND SOCIAL COGNITION IN DELUSIONAL PSYCHOSES
por: Díaz-Caneja, Covadonga, et al.
Publicado: (2020)

M222. SURVEY RESULTS FROM TURKEY: KNOWLEDGE ABOUT SCHIZOPHRENIA, PUBLIC STIGMA AND DISCRIMINATION BECAUSE OF SCHIZOPHRENIA
por: Haldun, Soygur, et al.
Publicado: (2020)

Differential effect of disease-associated ST8SIA2 haplotype on cerebral white matter diffusion properties in schizophrenia and healthy controls
por: Fullerton, Janice M., et al.
Publicado: (2018)

T219. REAL LIFE FUNCTIONING IN 22Q11 DELETION SYNDROME (DS) IN COMPARISON TO SCHIZOPHRENIA SUBJECTS: STUDY ON PSYCHOSES VULNERABILITY FACTORS. DATA FROM THE MULTICENTER STUDY OF THE ITALIAN NETWORK FOR RESEARCH ON PSYCHOSES
por: Carlone, Luca, et al.
Publicado: (2020)

M73. DRIVING ABILITIES IN PATIENTS WITH SCHIZOPHRENIA
por: Pardeller, Silvia, et al.
Publicado: (2020)

M190. USE OF NULL PRONOUNS IN SCHIZOPHRENIA
por: Chaves, Monica, et al.
Publicado: (2020)

M168. CLINICAL-ANATOMICAL PHENOTYPES OF SCHIZOPHRENIA
por: Kirschner, Matthias, et al.
Publicado: (2020)

M109. WEIGHT GAIN AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
Publicado: (2020)

Gene Expression Analysis Implicates a Death Receptor Pathway in Schizophrenia Pathology
por: Catts, Vibeke Sørensen, et al.
Publicado: (2012)

M64. ADDRESSING THE ROLE OF TIMING ON COGNITION IN SCHIZOPHRENIA
por: Alústiza, Irene, et al.
Publicado: (2020)

M117. ELUCIDATING ARCHITECTURE OF NEGATIVE SYNDROME IN SCHIZOPHRENIA
por: San Ang, Mei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mshagmf45b3707e888k227k4qt